These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23334943)

  • 1. High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.
    Murtola TJ; Kujala PM; Tammela TL
    Prostate; 2013 Jun; 73(9):923-31. PubMed ID: 23334943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).
    Schröder F; Bangma C; Angulo JC; Alcaraz A; Colombel M; McNicholas T; Tammela TL; Nandy I; Castro R
    Eur Urol; 2013 May; 63(5):779-87. PubMed ID: 23176897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
    Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
    BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-alpha Reductase inhibitors in prostate cancer: from clinical trials to clinical practice.
    Ehdaie B; Touijer KA
    Eur Urol; 2013 May; 63(5):788-9; discussion 790-1. PubMed ID: 23305882
    [No Abstract]   [Full Text] [Related]  

  • 5. Early dutasteride monotherapy in men with detectable serum prostate-specific antigen levels following radical prostatectomy: A prospective trial.
    Shin YS; Lee JW; Kim MK; Jeong YB; Park SC
    Investig Clin Urol; 2017 Mar; 58(2):98-102. PubMed ID: 28261678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy.
    Shah SK; Trump DL; Sartor O; Tan W; Wilding GE; Mohler JL
    J Urol; 2009 Feb; 181(2):621-6. PubMed ID: 19091347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: a pilot study.
    Perrotti M; Jain R; Abriel LM; Baroni TE; Corbett AB; Tenenbaum SA
    Urol Oncol; 2012; 30(2):133-8. PubMed ID: 20800512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
    Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
    Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins.
    Aoun F; Albisinni S; Henriet B; Tombal B; Van Velthoven R; Roumeguère T
    Scand J Urol; 2017 Feb; 51(1):20-26. PubMed ID: 27910728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
    Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
    JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.
    Murtola TJ; Karppa EK; Taari K; Talala K; Tammela TL; Auvinen A
    Int J Cancer; 2016 Jun; 138(12):2820-8. PubMed ID: 26804670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5α-Reductase Inhibitors and Risk of Prostate Cancer Death.
    Bonde Miranda T; Garmo H; Stattin P; Robinson D
    J Urol; 2020 Oct; 204(4):714-719. PubMed ID: 32243243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.
    Abdel Raheem A; Chang KD; Alenzi MJ; Ham WS; Han WK; Choi YD; Rha KH
    Int J Urol; 2018 Dec; 25(12):1006-1014. PubMed ID: 30276864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.
    Liesenfeld L; Kron M; Gschwend JE; Herkommer K
    J Urol; 2017 Jan; 197(1):143-148. PubMed ID: 27418452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality.
    Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
    JAMA Oncol; 2022 Jul; 8(7):1019-1026. PubMed ID: 35587340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.